We actually talked this about a while back and looking at how the trail is set up an FDA advisory board to take an early look was not included as part of the trail.
Hey Jess, there are examples of phase 3 double blind studies being stopped early by the independent Data Monitoring Committee (DMC) due to positive efficacy results. Personally, I think the chances for that are pretty low. What seems much more likely is that the company is acquired before the trial is completed. It’s also very possible that Auph’s management team might feel they let go of their previous company for too little $ in retrospect, so now they’re willing to take this one into commercialization to get maximum value...IMHO. I believe this is one of the reasons we saw a change at CEO before Ph2b results came out.
News 
Market Data 
Discover 
